Genmab — April 2017
-
Helt med på, at det er andre medicinalfirmaer, der starter forsøgene og selv finianserer dem. Og man må gå ud fra, at de har en begrundet antagelse (efter in vitro forsøg) om, at det vil forbedre virkningen af deres eget præparat. Forsøgene er jo ikke just gratis hverken økonomisk eller menneskeligt. Tænker bare, at det er et ret stort antal forsøg, hvor kombi-præparatet skal passe lige til højrebenet, og at vi nok ikke skal forvente success i dem alle...
-
Teknisk analyse Genmab og Novo: https://play.borsen.dk/social/58fdabdd45628ff817201c3f
-
Dara - Nivolumab i solide tumorer forventet start 28 april. https://clinicaltrials.gov/ct2/show/NCT03098550?term=daratumumab+nsclc&rank=2
-
Immunotherapy-pioneer James Allison, general article : https://www.technologyreview.com/s/604086/immunotherapy-pioneer-james-allison-has-unfinished-business-with-cancer/
-
@JohnW - nææh ikke rigtigt, men stadig en grøn/plus dag og det kan man jo ikke kimse af.
-
Så sandt @BobTheThird, så sandt.
-
JNJ Pharmaceutical Business Review 17. maj
-
Haven't heard anything about the 2nd NICE Committee meeting on Apr 20, thought those meetings were public. Looks like we have to wait until July for the small chance they will surprise us with a UK approval. https://www.nice.org.uk/guidance/indevelopment/gid-ta10076
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind